Health tech investors are looking at bigger betsnews2026-09-03T13:45:07+00:00September 3rd, 2026|Endpoints News|
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialnews2026-09-03T11:12:36+00:00September 3rd, 2026|Endpoints News|
Superluminal secures $60M for Phase 1 of genetic obesity drugnews2026-09-03T10:00:59+00:00September 3rd, 2026|Endpoints News|
GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontnews2026-09-03T09:59:27+00:00September 3rd, 2026|Endpoints News|
Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsnews2026-09-03T01:35:17+00:00September 3rd, 2026|Endpoints News|
FDA leaders project enhanced scrutiny of foreign datanews2026-09-02T19:21:51+00:00September 2nd, 2026|Endpoints News|
Novartis CAR-T deaths raise questions over acceptable autoimmune risknews2026-09-02T18:48:44+00:00September 2nd, 2026|Endpoints News|
CBER official overruled review team’s rejection of new Replimune melanoma drugnews2026-09-02T16:02:32+00:00September 2nd, 2026|Endpoints News|
UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington’s gene therapynews2026-09-02T15:07:53+00:00September 2nd, 2026|Endpoints News|
Teva says gluten challenge study succeeds in celiac diseasenews2026-09-02T14:58:42+00:00September 2nd, 2026|Endpoints News|
